BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1083 related articles for article (PubMed ID: 19377506)

  • 1. Targeting DNA topoisomerase II in cancer chemotherapy.
    Nitiss JL
    Nat Rev Cancer; 2009 May; 9(5):338-50. PubMed ID: 19377506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular cloning and expression of the Candida albicans TOP2 gene allows study of fungal DNA topoisomerase II inhibitors in yeast.
    Keller BA; Patel S; Fisher LM
    Biochem J; 1997 May; 324 ( Pt 1)(Pt 1):329-39. PubMed ID: 9164874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Molecular determinants of response to topoisomerase II inhibitors].
    Lansiaux A; Pourquier P
    Bull Cancer; 2011 Nov; 98(11):1299-310. PubMed ID: 22023806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-molecule Förster resonance energy transfer (FRET) analysis discloses the dynamics of the DNA-topoisomerase II (Top2) interaction in the presence of TOP2-targeting agents.
    Huang WC; Lee CY; Hsieh TS
    J Biol Chem; 2017 Jul; 292(30):12589-12598. PubMed ID: 28630044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies on Non-synonymous Polymorphisms Altering Human DNA Topoisomerase II-Alpha Interaction with Amsacrine and Mitoxantrone: An
    Farsani FM; Ganjalikhany MR; Vallian S
    Curr Cancer Drug Targets; 2017; 17(7):657-668. PubMed ID: 27834128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms to Repair Stalled Topoisomerase II-DNA Covalent Complexes.
    Swan RL; Cowell IG; Austin CA
    Mol Pharmacol; 2022 Jan; 101(1):24-32. PubMed ID: 34689119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA topoisomerase II and its growing repertoire of biological functions.
    Nitiss JL
    Nat Rev Cancer; 2009 May; 9(5):327-37. PubMed ID: 19377505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances in the development of dual topoisomerase I and II inhibitors as anticancer drugs.
    Salerno S; Da Settimo F; Taliani S; Simorini F; La Motta C; Fornaciari G; Marini AM
    Curr Med Chem; 2010; 17(35):4270-90. PubMed ID: 20939813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Roles of nonhomologous end-joining pathways in surviving topoisomerase II-mediated DNA damage.
    Malik M; Nitiss KC; Enriquez-Rios V; Nitiss JL
    Mol Cancer Ther; 2006 Jun; 5(6):1405-14. PubMed ID: 16818498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The topoisomerase IIbeta circular clamp arrests transcription and signals a 26S proteasome pathway.
    Xiao H; Mao Y; Desai SD; Zhou N; Ting CY; Hwang J; Liu LF
    Proc Natl Acad Sci U S A; 2003 Mar; 100(6):3239-44. PubMed ID: 12629207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic evidence for involvement of two distinct nonhomologous end-joining pathways in repair of topoisomerase II-mediated DNA damage.
    Adachi N; Iiizumi S; So S; Koyama H
    Biochem Biophys Res Commun; 2004 Jun; 318(4):856-61. PubMed ID: 15147950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stabilization of eukaryotic topoisomerase II-DNA cleavage complexes.
    Wilstermann AM; Osheroff N
    Curr Top Med Chem; 2003; 3(3):321-38. PubMed ID: 12570766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. On the structural basis and design guidelines for type II topoisomerase-targeting anticancer drugs.
    Wu CC; Li YC; Wang YR; Li TK; Chan NL
    Nucleic Acids Res; 2013 Dec; 41(22):10630-40. PubMed ID: 24038465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The anti-neoplastic and novel topoisomerase II-mediated cytotoxicity of neoamphimedine, a marine pyridoacridine.
    Marshall KM; Matsumoto SS; Holden JA; Concepción GP; Tasdemir D; Ireland CM; Barrows LR
    Biochem Pharmacol; 2003 Aug; 66(3):447-58. PubMed ID: 12907244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The top2-5 mutant of yeast topoisomerase II encodes an enzyme resistant to etoposide and amsacrine.
    Jannatipour M; Liu YX; Nitiss JL
    J Biol Chem; 1993 Sep; 268(25):18586-92. PubMed ID: 8395511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eukaryotic DNA topoisomerases mediated DNA cleavage induced by a new inhibitor: NSC 665517.
    Gupta M; Abdel-Megeed M; Hoki Y; Kohlhagen G; Paull K; Pommier Y
    Mol Pharmacol; 1995 Oct; 48(4):658-65. PubMed ID: 7476891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice.
    Fortune JM; Osheroff N
    Prog Nucleic Acid Res Mol Biol; 2000; 64():221-53. PubMed ID: 10697411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drugs acting on DNA topoisomerases: recent advances and future perspectives.
    Gatto B; Capranico G; Palumbo M
    Curr Pharm Des; 1999 Mar; 5(3):195-215. PubMed ID: 10066890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Broken by the Cut: A Journey into the Role of Topoisomerase II in DNA Fragility.
    Atkin ND; Raimer HM; Wang YH
    Genes (Basel); 2019 Oct; 10(10):. PubMed ID: 31614754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topoisomerase enzymes as drug targets.
    Guichard SM; Danks MK
    Curr Opin Oncol; 1999 Nov; 11(6):482-9. PubMed ID: 10550012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 55.